Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study
Given the current scarcity of curative treatment of COVID-19, the search for an effective treatment modality among all available medications has become a priority. This study aimed at investigating the role of functional inhibitors of acid sphingomyelinase (FIASMAs) on in-hospital COVID-19 mortality...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/3/226 |
| _version_ | 1827601935281160192 |
|---|---|
| author | Gil Darquennes Pascal Le Corre Olivier Le Moine Gwenolé Loas |
| author_facet | Gil Darquennes Pascal Le Corre Olivier Le Moine Gwenolé Loas |
| author_sort | Gil Darquennes |
| collection | DOAJ |
| description | Given the current scarcity of curative treatment of COVID-19, the search for an effective treatment modality among all available medications has become a priority. This study aimed at investigating the role of functional inhibitors of acid sphingomyelinase (FIASMAs) on in-hospital COVID-19 mortality. In this retrospective cohort study, we included adult in-patients with laboratory-confirmed COVID-19 between 1 March 2020 and 31 August 2020 with definite outcomes (discharged hospital or deceased) from Erasme Hospital (Brussels, Belgium). We used univariate and multivariate logistic regression models to explore the risk factors associated with in-hospital mortality. We included 350 patients (205 males, 145 females) with a mean age of 63.24 years (SD = 17.4, range: 21–96 years). Seventy-two patients died in the hospital and 278 were discharged. The four most common comorbidities were hypertension (184, 52.6%), chronic cardiac disease (110, 31.4%), obesity (96, 27.8%) and diabetes (95, 27.1%). Ninety-three participants (26.6%) received a long-term prescription for FIASMAs. Among these, 60 (64.5%) received amlodipine. For FIASMAs status, multivariable regression showed increasing odds ratio (OR) for in-hospital deaths associated with older age (OR 1.05, 95% CI: 1.02–1.07; <i>p</i> = 0.00015), and higher prevalence of malignant neoplasm (OR 2.09, 95% CI: 1.03–4.22; <i>p</i> = 0.039). Nonsignificant decreasing OR (0.53, 95% CI: 0.27–1.04; <i>p</i> = 0.064) was reported for FIASMA status. For amlodipine status, multivariable regression revealed increasing OR of in-hospital deaths associated with older age (OR 1.04, 95% CI: 1.02–1.07; <i>p</i> = 0.0009), higher prevalence of hypertension (OR 2.78, 95% CI: 1.33–5.79; <i>p</i> = 0.0062) and higher prevalence of malignant neoplasm (OR 2.71, 95% CI: 1.23–5.97; <i>p</i> = 0.013), then secondarily decreasing OR of in-hospital death associated with long-term treatment with amlodipine (OR 0.24, 95% CI: 0.09–0.62; <i>p</i> = 0.0031). Chronic treatment with amlodipine could be significantly associated with low mortality of COVID-19 in-patients. |
| first_indexed | 2024-03-09T05:07:25Z |
| format | Article |
| id | doaj.art-ddd386c52ceb4c8ca4a14620305f87b0 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T05:07:25Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-ddd386c52ceb4c8ca4a14620305f87b02023-12-03T12:53:32ZengMDPI AGPharmaceuticals1424-82472021-03-0114322610.3390/ph14030226Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort StudyGil Darquennes0Pascal Le Corre1Olivier Le Moine2Gwenolé Loas3Department of Psychiatry, Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, BelgiumPôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, FranceDepartment of Medical Gastro-Enterology, Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, BelgiumDepartment of Psychiatry, Hôpital Erasme, Université libre de Bruxelles (ULB), 1050 Brussels, BelgiumGiven the current scarcity of curative treatment of COVID-19, the search for an effective treatment modality among all available medications has become a priority. This study aimed at investigating the role of functional inhibitors of acid sphingomyelinase (FIASMAs) on in-hospital COVID-19 mortality. In this retrospective cohort study, we included adult in-patients with laboratory-confirmed COVID-19 between 1 March 2020 and 31 August 2020 with definite outcomes (discharged hospital or deceased) from Erasme Hospital (Brussels, Belgium). We used univariate and multivariate logistic regression models to explore the risk factors associated with in-hospital mortality. We included 350 patients (205 males, 145 females) with a mean age of 63.24 years (SD = 17.4, range: 21–96 years). Seventy-two patients died in the hospital and 278 were discharged. The four most common comorbidities were hypertension (184, 52.6%), chronic cardiac disease (110, 31.4%), obesity (96, 27.8%) and diabetes (95, 27.1%). Ninety-three participants (26.6%) received a long-term prescription for FIASMAs. Among these, 60 (64.5%) received amlodipine. For FIASMAs status, multivariable regression showed increasing odds ratio (OR) for in-hospital deaths associated with older age (OR 1.05, 95% CI: 1.02–1.07; <i>p</i> = 0.00015), and higher prevalence of malignant neoplasm (OR 2.09, 95% CI: 1.03–4.22; <i>p</i> = 0.039). Nonsignificant decreasing OR (0.53, 95% CI: 0.27–1.04; <i>p</i> = 0.064) was reported for FIASMA status. For amlodipine status, multivariable regression revealed increasing OR of in-hospital deaths associated with older age (OR 1.04, 95% CI: 1.02–1.07; <i>p</i> = 0.0009), higher prevalence of hypertension (OR 2.78, 95% CI: 1.33–5.79; <i>p</i> = 0.0062) and higher prevalence of malignant neoplasm (OR 2.71, 95% CI: 1.23–5.97; <i>p</i> = 0.013), then secondarily decreasing OR of in-hospital death associated with long-term treatment with amlodipine (OR 0.24, 95% CI: 0.09–0.62; <i>p</i> = 0.0031). Chronic treatment with amlodipine could be significantly associated with low mortality of COVID-19 in-patients.https://www.mdpi.com/1424-8247/14/3/226functional inhibitors of acid sphingomyelinase (FIASMAs), COVID-19SARS-CoV-2mortalityamlodipine |
| spellingShingle | Gil Darquennes Pascal Le Corre Olivier Le Moine Gwenolé Loas Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study Pharmaceuticals functional inhibitors of acid sphingomyelinase (FIASMAs), COVID-19 SARS-CoV-2 mortality amlodipine |
| title | Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study |
| title_full | Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study |
| title_fullStr | Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study |
| title_full_unstemmed | Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study |
| title_short | Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study |
| title_sort | association between functional inhibitors of acid sphingomyelinase fiasmas and reduced risk of death in covid 19 patients a retrospective cohort study |
| topic | functional inhibitors of acid sphingomyelinase (FIASMAs), COVID-19 SARS-CoV-2 mortality amlodipine |
| url | https://www.mdpi.com/1424-8247/14/3/226 |
| work_keys_str_mv | AT gildarquennes associationbetweenfunctionalinhibitorsofacidsphingomyelinasefiasmasandreducedriskofdeathincovid19patientsaretrospectivecohortstudy AT pascallecorre associationbetweenfunctionalinhibitorsofacidsphingomyelinasefiasmasandreducedriskofdeathincovid19patientsaretrospectivecohortstudy AT olivierlemoine associationbetweenfunctionalinhibitorsofacidsphingomyelinasefiasmasandreducedriskofdeathincovid19patientsaretrospectivecohortstudy AT gwenoleloas associationbetweenfunctionalinhibitorsofacidsphingomyelinasefiasmasandreducedriskofdeathincovid19patientsaretrospectivecohortstudy |